New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Development of Anti-inflammatory Bispecific anti-TNF-αVHH anti-IL-6 Antibody Fusion for the Treatment of Inflammatory Retinal Diseases
